SELECT Pre-Clinical Trial of Prostate Cancer
选择性前列腺癌临床前试验
基本信息
- 批准号:7176801
- 负责人:
- 金额:$ 25.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-02-07 至 2010-12-31
- 项目状态:已结题
- 来源:
- 关键词:AdenocarcinomaAdvanced Malignant NeoplasmAgeAmericanAnimal ModelAnimalsAntioxidantsApoptosisApoptoticAreaBinding ProteinsBiological MarkersBreedingCDKN1A geneCancer BiologyCancer EtiologyCaspaseCell AgingCessation of lifeChemopreventionChemopreventive AgentControlled Clinical TrialsCyclin-Dependent Kinase InhibitorDNA FragmentationDataDevelopmentDiagnosisDigital Rectal ExaminationDisease ManagementDouble-Blind MethodE-CadherinFundingFutureGalactosidaseGamma-glutamyl transferaseGenesGlucosephosphate DehydrogenaseGlutathione S-TransferaseGrowth FactorHumanIndia ink stainIndividualInstitutionInsulinInsulin-Like Growth Factor IIntegrinsInternationalIntervention TrialKnowledgeL-SelenomethionineLeadLipid PeroxidationMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of prostateMediatingMetastatic Prostate CancerMethodsModelingModificationMolecularMonitorMusNAD(P)H oxidaseNF-kappa BNational Cancer InstituteNeoplasm MetastasisOral AdministrationOutcomeOxidative StressPathway interactionsPhasePlacebo ControlPreventiveProstateProstate Cancer Prevention TrialProtein FamilyProtein p53ProteinsPublic HealthPurposeRandomizedResearchResearch PersonnelRiskSOD2 geneSamplingSeleniumSelenium/vitamin ESerumSouthwest Oncology GroupStagingStudy SubjectSuggestionSuperoxide DismutaseTelomeraseTestingTherapeuticThioredoxinTimeTissuesTransgenic OrganismsTumor WeightsUnited StatesUniversitiesVitamin EVitamin E AcetateWeekWeightWisconsinWorkYeastsage effectanimal colonybasecarcinogenesiscatalasedesignenzyme activityglutathione peroxidaseglutathione synthasehuman diseaseinsulin-like growth factor binding protein-related protein 1interestmalemenmouse modelnoveloncoprotein p21p27 Cell Cycle Proteinp27 Enzyme Inhibitorperoxiredoxin 5pre-clinicalpreclinical studyprogramsprospectiveprostate cancer preventionresearch studyresponseribosomal protein L19senescenceserum PSAtreatment effecttumor growthtumor progressiontumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Prostate Cancer (PCa), next only to lung cancer, is the second leading cause of cancer-related deaths in American males. At present, there are inadequate treatment options for the management of PCa. The public health impact from PCa has spawned tremendous interest in Chemoprevention trials. Preclinical, epidemiological, and phase III randomized, placebo-controlled clinical trials suggest that selenium and vitamin E could be effective in PCa prevention. Based on these studies, 'Selenium and Vitamin E Chemoprevention Trial (SELECT)' has been initiated. It is a randomized, prospective, double-blind study (7- 12 years) designed to determine whether selenium and vitamin E alone and in combination could reduce the risk of PCa among healthy men. This is an outstanding effort of its kind. However, several investigators are critical about the rationale whereas several others have arguments. Two popular questions in this direction are: (1) whether there are sufficient data on these supplements to justify this trial; and (2) whether more biomarkers (which could suggest the possible molecular mechanisms involved) should be included in SELECT trial. The present proposal, on a pre-clinical SELECT Trial in a well-established mouse model of prostate carcinogenesis, should provide answers to these questions. The hypothesis of this proposal is that a combination of vitamin E and selenium will provide synergistic chemopreventive effect against PCa via inhibiting oxidative stress and enhancing apoptotic and/or senescence response. Employing transgenic adenocarcinoma mouse prostate (TRAMP) mice, we propose to conduct a pre-clinical Chemoprevention/ intervention trial that mimics SELECT trial (in human) to determine whether selenium and vitamin E alone and in combination can inhibit PCa development and its metastasis. We will also study the involvement of oxidative stress, apoptosis and cellular senescence during PCa development and its inhibition by vitamin E and/or selenium. Finally, we will study the involvement of NF-kappaB pathway during the modulation in oxidative stress and apoptotic/senescence response of selenium and/or vitamin E treatments in TRAMP model. We believe that a successful completion of our study will provide important information regarding the possible outcome of SELECT trial in humans and may even provide novel information on which suggestions could be made for the modifications for the ongoing or future trials.
描述(由申请人提供):仅次于肺癌的前列腺癌(PCA)是美国男性与癌症相关死亡的第二大原因。目前,PCA管理的治疗选择不足。 PCA的公共卫生影响产生了对化学预防试验的极大兴趣。临床前,流行病学和第三阶段随机,安慰剂对照的临床试验表明,硒和维生素E可以有效预防PCA。基于这些研究,已经开始了“硒和维生素E化学预防试验(Select)”。这是一项随机,前瞻性,双盲研究(7至12年),旨在确定单独的硒和维生素E是否可以降低健康男性PCA的风险。这是同类的杰出努力。但是,一些调查人员对理由至关重要,而其他一些调查人员也有争论。朝这个方向的两个流行问题是:(1)这些补充剂是否有足够的数据来证明该试验的合理性; (2)是否应将更多的生物标志物(可能暗示可能涉及的分子机制)包括在某些试验中。本提案是在临床前的精选试验中,在完善的前列腺致癌小鼠模型中,应为这些问题提供答案。该提议的假设是,维生素E和硒的结合将通过抑制氧化应激和增强凋亡和/或衰老反应来对PCA提供协同的化学预防作用。我们采用转基因腺癌小鼠前列腺(流浪汉)小鼠,我们建议进行一项临床前化学预防/干预试验,该试验模拟选择试验(人类),以确定单独的硒和维生素E是否可以抑制PCA的发育及其转移。我们还将研究PCA发育过程中氧化应激,凋亡和细胞衰老的参与及其对维生素E和/或硒的抑制作用。最后,我们将研究在调节过程中NF-kappab途径在氧化应激以及硒和/或维生素E处理中的氧化应激和凋亡/衰老反应中的参与。我们认为,成功完成我们的研究将提供有关人类特定试验可能结果的重要信息,甚至可以提供新的信息,以提出哪些建议对正在进行的或将来的试验进行修改。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nihal Ahmad其他文献
Nihal Ahmad的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nihal Ahmad', 18)}}的其他基金
Combined inhibition of PLK1 and NOTCH for melanoma management
联合抑制 PLK1 和 NOTCH 治疗黑色素瘤
- 批准号:
10481129 - 财政年份:2023
- 资助金额:
$ 25.08万 - 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
- 批准号:
10481027 - 财政年份:2022
- 资助金额:
$ 25.08万 - 项目类别:
Functional and Therapeutic Significance of PLK4 in Melanoma
PLK4 在黑色素瘤中的功能和治疗意义
- 批准号:
10442947 - 财政年份:2022
- 资助金额:
$ 25.08万 - 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
- 批准号:
10593106 - 财政年份:2022
- 资助金额:
$ 25.08万 - 项目类别:
Functional and Therapeutic Significance of PLK4 in Melanoma
PLK4 在黑色素瘤中的功能和治疗意义
- 批准号:
10671687 - 财政年份:2022
- 资助金额:
$ 25.08万 - 项目类别:
Role of sirtuin 6 in melanoma development and progression
Sirtuin 6 在黑色素瘤发生和进展中的作用
- 批准号:
10595641 - 财政年份:2021
- 资助金额:
$ 25.08万 - 项目类别:
Role of sirtuin 6 in melanoma development and progression
Sirtuin 6 在黑色素瘤发生和进展中的作用
- 批准号:
10426079 - 财政年份:2021
- 资助金额:
$ 25.08万 - 项目类别:
Role of polo like kinase 4 in melanomagenesis and melanoma progression
Polo 样激酶 4 在黑色素瘤发生和黑色素瘤进展中的作用
- 批准号:
10046297 - 财政年份:2018
- 资助金额:
$ 25.08万 - 项目类别:
Role of polo like kinase 4 in melanomagenesis and melanoma progression
Polo 样激酶 4 在黑色素瘤发生和黑色素瘤进展中的作用
- 批准号:
10421255 - 财政年份:2018
- 资助金额:
$ 25.08万 - 项目类别:
Role of polo like kinase 4 in melanomagenesis and melanoma progression
Polo 样激酶 4 在黑色素瘤发生和黑色素瘤进展中的作用
- 批准号:
9551225 - 财政年份:2018
- 资助金额:
$ 25.08万 - 项目类别:
相似海外基金
Cause and Effect Relationships Between Glycation and the Ancestry Specific Tumor Stroma
糖化与祖先特异性肿瘤基质之间的因果关系
- 批准号:
10586185 - 财政年份:2023
- 资助金额:
$ 25.08万 - 项目类别:
Ovarian Inflammaging as a Mechanism for Ovarian Cancer
卵巢炎症是卵巢癌的机制
- 批准号:
10645119 - 财政年份:2021
- 资助金额:
$ 25.08万 - 项目类别:
Ovarian Inflammaging as a Mechanism for Ovarian Cancer
卵巢炎症是卵巢癌的机制
- 批准号:
10532678 - 财政年份:2021
- 资助金额:
$ 25.08万 - 项目类别:
Molecular determinants of lung cancer in HIV infected and uninfected individuals in Uganda and Tanzania
乌干达和坦桑尼亚艾滋病毒感染者和未感染者肺癌的分子决定因素
- 批准号:
10084628 - 财政年份:2020
- 资助金额:
$ 25.08万 - 项目类别:
Molecular determinants of lung cancer in HIV infected and uninfected individuals in Uganda and Tanzania
乌干达和坦桑尼亚艾滋病毒感染者和未感染者肺癌的分子决定因素
- 批准号:
10267199 - 财政年份:2020
- 资助金额:
$ 25.08万 - 项目类别: